The same authors have shown that increased hypomethylation in the HRAS promoter was inversely associated with lower expression in bladder cancer, suggesting that other genetic or epigenetic factors may contribute to HRAS-mediated tumorigenesis. This evidence concerns the gene HRAS and urinary bladder cancer.